Background: Cancer patients often do not make informed decisions about clinical trial
Implications for Practice: This paper describes evidence about a decision tool to support patients' decisions about trial participation. By improving knowledge, helping patients clarify preferences for participation, and facilitating conversations about trials, DAs could lead to decisions about participation that better match patients' preferences, promoting patient-centered care and the ethical conduct of clinical research.
Gap between current and best practice: Although cancer clinical trials are an important treatment option for many cancer patients and necessary for improving cancer care and outcomes, there is a well-documented lack of informed decision making by patients facing choices about clinical trials and poor understanding of trials even among participants.
Interventions are needed to better support patients' decisions about trial participation.
Learning Objectives:
Best 
BACKGROUND
Cancer clinical trials are essential to evaluate new therapies and advance evidence based treatments. However, despite the widespread availability of cancer clinical trials in academic and non-academic settings, patients often are not well informed about trials and do not make informed decisions about participation. Many patients harbor therapeutic misconceptions about the aim of clinical trials [1, 2] and overestimate benefits of standard treatment [3] . In a recent meta-analysis of 103 studies, over 25% of clinical trial participants did not understand the nature of the study they were participating in or the voluntary nature of participation [4] . Only about 50% of participants understood central trial concepts such as the use of placebos or randomization [4] . Furthermore, members of the general public frequently have misconceptions about clinical trials, with nearly half of respondents believing that research participants do not always receive the best possible care [5] .
Without an adequate understanding of trials and trial procedures, patients cannot make a fully informed decision about participation, a principal tenet of the ethical conduct of clinical research. While a number of interventions have been developed to improve clinical trial informed consent, nearly all focus exclusively on improving patients' knowledge [6, 7] . Even with the implementation of such interventions, a recent meta-analysis found that participant understanding of important concepts essential for informed consent has not increased over the 3 decades of studies examined [4] . To improve cancer clinical trial decision quality, interventions must go beyond knowledge provision to address aspects such as preference deliberation and decision preparedness, guiding patients through the trial decision making process [6, 8] .
Patient decision aids (DAs; Figure 1 ) can be used to support high-quality cancer clinical trial decisions. In a variety of contexts, DAs have reduced patients' uncertainty about health decisions, improved patients' knowledge about decisions, improved patient-provider decision communication, and improved the match between patients' values and their health choices [9] .
DAs incorporate values clarification exercises that help individuals address fears, concerns, and preferences for options. These concerns and preferences might be particularly important for racial and ethnic minority populations typically excluded from trials, in part because of concerns and misinformation about clinical research [10, 11] . By improving knowledge about trials, clarifying patients' preferences for participation, and facilitating conversations about trials, DAs could improve decisions about participation that better match patients' preferences, promoting patient-centered care and the ethical conduct of clinical research. They could also improve trial retention rates, particularly among those who hesitate to participate based on misinformation about trials, if patients become more informed and aware of trials and details prior to participation. Given that there is often limited time for deliberation once a patient becomes trialeligible, implementing DAs about cancer clinical trials at multiple points in the cancer care continuum, even before patients are eligible for a trial, can prepare patients to make a choice about trial participation if or when one is offered to them.
The purpose of this study was to compare a web-based DA to our cancer center's usual care website in a randomized trial, examining whether and how the DA improves four elements of decision making about cancer clinical trial participation: knowledge, self-efficacy, preparedness to make a decision about trial participation, and intent to participate in a trial. Our hypothesis was that implementing the DA would improve each of these outcomes, increasing knowledge, self-efficacy, preparedness to make a decision about trial participation, and intent to participate in a trial among recently diagnosed cancer patients. A secondary hypothesis was that the DA would improve outcomes at a greater rate for racial minorities.
METHODS

Decision Aid
The eight-section web-based DA was developed based on cancer survivor input in accordance with best practices in health literacy. t concentrates on knowledge, empowerment, and values clarification, aiming to correct common misconceptions about trials while promoting preference deliberation ( Figure 1 In the current phase, we evaluated the effectiveness of the web-based DA in comparison to an enhanced usual care control in a diverse population of newly diagnosed cancer patients.
The trial was registered with clinicaltrials.gov (protocol number: NCT01964222) prior to data collection [12] .
Participants
Participants were recruited in various cancer clinics within a major urban academic medical center. Adults 18 or older who had been diagnosed with cancer in the past six months and who had not previously participated in a cancer clinical trial were eligible to participate.
Consistent with the intent of the tool and the fact that trial eligibility can change across the care continuum, patients were included whether or not they were a trial candidate at the time of study enrollment. Eligible participants were identified through clinician referrals and/or through review of medical records by a member of the research team.
Data Collection
Eligible patients were approached during clinic visits. At the direction of clinic staff, trained research assistants invited eligible patients to participate in the waiting room and/or in the exam room. Eligible patients had had no prior contact about the study. After a brief explanation of the study, interested individuals completed a brief screening survey to confirm eligibility.
Written consent was obtained from those who were interested and eligible prior to viewing any additional study materials. Participants were then allocated by a computer-generated random number sequence to one of two study conditions: DA or enhanced usual care (UC). Those randomized to the DA group were instructed to view the web-based DA ( home with a link to the website. For participants who opted to complete the intervention and survey at the clinic, research assistants remained available to participants if they encountered technical challenges, however, to reduce response bias, they did not stay with the participant as he/she completed the survey.. Participants were allowed as much time as they needed to navigate the website and to complete the survey. They were provided a $20 gift card for their time.
Measures
Knowledge
Eleven objective knowledge items evaluated how well participants understood cancer clinical trials after viewing their assigned website (Appendix A). An overall knowledge score was calculated for each participant with the percentage of items correctly answered, consistent with the validated measure's scoring procedures [13] [14] [15] . We examined whether there were differences between the two groups in the average percentage of correct answers. Participants were also asked to rank their self-perceived knowledge on a single-item 5-point Likert scale from 1=not at all knowledgeable to 5=completely knowledgeable.
Self-Efficacy for Finding Information About Cancer Clinical Trials
Self-efficacy for finding information about cancer clinical trials was measured on a single-item 5-point scale with higher scores indicating greater self-efficacy for finding information.
Decisional Conflict
Evaluation of decisional conflict consisted of two subscales: the Values Clarity Subscale and the Uncertainty Subscale of the low literacy version of the Decisional Conflict Scale [16] . Each contains two items with three response categories. Following standard scoring guidelines for the validated measure, each item was scored, then the sum was divided by 2 and multiplied by 25 to produce overall "Values Clarity" and "Uncertainty" scores, respectively. Scores ranged from 1 to 100, with higher values representing less values clarity and less certainty, respectively.
Clarity of Opinions
Clarity of opinions about cancer clinical trials was measured on a single-item 5-point scale with higher scores indicating clearer opinions.
Intent to Participate
Intent to participate in a cancer clinical trial was measured on a single-item 5-point scale with higher scores indicating greater intent to participate.
Intent to Encourage Others to Participate
Intent to encourage others to participate in a cancer clinical trial was measured on a single-item 5-point scale with higher scores indicating greater intent to encourage others to participate.
Decision Readiness
Readiness to make a decision about whether to participate in a cancer clinical trial was measured on a single-item 5-point scale with higher scores indicating greater readiness to make a decision.
Perceptions of Cancer Clinical Trials
Participants' perceptions of the pleasantness, safeness, easiness, helpfulness, value, convenience, and goodness of cancer clinical trials were measured with individual items on a 7-point Likert scale from 1=very unpleasant, very unsafe, etc. to 7=very pleasant, very safe, etc.
Implementation Outcomes
To evaluate the potential for implementation of the web-based DA, three implementation outcomes were examined: time spent on the website, number of visits to the website, number of participants who visited each page of the website in the DA group.
Sociodemographic Information
Sociodemographic information was collected including age, gender, cancer type, education, income, ethnicity, race, language, and health literacy level [17] .
Data Analysis
All analyses were conducted using Stata version 13. Descriptive statistics were calculated for continuous and categorical variables. Bivariate analyses explored the relationship between randomized group (DA or UC) and outcomes. Primary outcomes were knowledge and decisional conflict; secondary outcomes were self-efficacy, intent to participate, decision readiness, and trial perceptions. Because the outcome variables for secondary outcomes may not be interval since they are measured using a Likert scale, we assessed the robustness of significant differences in outcome by group assignment using non-parametric chi-square tests. As the nonparametric analyses showed the same results as the parametric analyses in terms of significant differences by group assignment for these outcome variables, we only present results from the parametric analyses. Controlling for whether or not participants had ever heard of cancer clinical trials and educational attainment, multivariable linear regression models examined group (DA or UC) on knowledge, self-efficacy for finding information about trials, decisional conflict (values clarity and uncertainty about choice), and intent to participate, decision readiness, and perceptions of cancer clinical trials. Sample size was set at 180 (90 per group) to achieve 80% power at α=0.05, using knowledge as the primary outcome and controlling for up to three covariates. Statistical significance was set at 0.05 using two-sided analyses. 55.0 (0.9) respectively: p=0.009), but did not significantly differ in any other measured demographic characteristics. Table 1 displays demographic characteristics of the final sample.
RESULTS
Participant Characteristics
There were no significant differences in demographic characteristics between individuals randomized to the DA vs. the UC. Most participants (162/177, 91.5%) chose to view the website at home rather than at their clinic visit, with 107 (60.5%) completing the survey by email, 44
(24.9%) by mail, and 11 (6.2%) by phone.
Bivariate Outcomes by Group
Participants in the DA group performed better on overall knowledge on the eleven-item knowledge scale, answering an average of 73.7% of the items (8.1/11) correctly, compared to 61.5% (6.8/11) in the UC group (p=0.0001) ( Table 2 ). The percentage of participants answering correctly was greater in the DA group than in the UC group for all items, with statistically significant differences between groups on four of the eleven items (Table 2 ). However, certain items were frequently answered incorrectly by participants in both groups. In particular, items about placebo use and study phases were answered correctly by fewer than half the participants in both the DA and UC conditions ( Table 2) . Because our outcome variables do not strictly meet the assumptions for OLS regressions, we ran alternatively specified models using ordered logit regression (Intent, clarity of values and uncertainty) and generalized linear models (knowledge) as a sensitivity analyses. There were no changes in the significance of these outcome variables after controlling for whether or not participants had heard of cancer clinical trials and educational attainment.
Multivariable Analyses
In exploratory analyses, we assessed whether race/ethnicity was associated with outcome variables. In multivariable analyses controlling for whether or not participants ever heard of cancer clinical trials and educational attainment, we found no significant difference when comparing White non-Hispanics to all Others in intent to participate, clarity of opinions, uncertainty, and knowledge.
Association of Objective Knowledge with Intent to Participate and Subjective Outcome Variables
We explored the association of the proportion of correct knowledge questions with individuals' intent to participate and subjective views on knowledge and decision readiness using pairwise correlations. We found no significant association with knowledge and intent to participate or intent to encourage others to participate. However, there were significant associations between knowledge and variables for self-perceived knowledge, clarity of opinions, uncertainty, and clarity of values, with higher levels of objective knowledge being associated with higher perceived knowledge and decision readiness (Table 5 ). These significant associations were maintained after controlling for group assignment, ever heard of cancer clinical trials, and educational attainment in multivariate regressions (data not shown in tables).
Decision Aid Implementation Outcomes
Of the 86 participants in the DA group, data on implementation outcomes was available for the 64 participants who opted to view the tool online rather than on paper. Moreover, the DA was received positively by patients even among older adults who were not comfortable using computers or the Internet. Our response rate (86%) and completion rate of those enrolled (90% in the DA group) was high for a study on newly diagnosed cancer patients.
By offering multiple methods to complete the DA in both web-and paper-based formats, inside and outside of the clinic environment, we were able to reach a range of participants. In our study, 61% of participants completed the study electronically outside of the clinic environment.
National studies of Internet use among older adults [18] suggest that approximately 58% of older adults use the Internet in their home, and this number is growing. Electronic DAs such as this one can be an important avenue for delivering cancer-related information, but steps should be taken to ensure that patients regardless of computer literacy can benefit from the information while there is still a sizable minority of the older adult population who might not be comfortable using computers.
The DA discussed much of the information identified by key stakeholders as essential for patients to understand about trial participation, to a diverse population of newly diagnosed cancer There are several reasons we might not have seen differences in intent to participate in trials. Intent to participate is often related to cancer stage, and our patients had a mix of cancer types and stages. It is possible that cancer type or stage contributed to this outcome, but given the diversity of patients in the study, we did not have the power to explore specific disease characteristics on outcomes. In addition, DAs are not designed to persuade individuals to participate or not in a particular trial, thus intent might not be expected to change as a result of this intervention. It is possible that retention rates could increase with the use of DAs as patients match their decision about participation to their preferences, but this study was not designed to measure changes in retention over time. Finally, intent was high in both groups. We did find qualitative information that supported increased intentions to participate after viewing the DA. In our study, we found that the DA website performed better than the usual care website among both White and non-White patients. This finding suggests that DAs could help mitigate some of the racial disparities in trial knowledge, and self-efficacy for finding information about trials. Future studies could look specifically at minority groups' responses to the DA and/or could develop targeted institutional based strategies to help address the disparities in trial enrollment rates.
It is important to interpret these findings in the context of the study. The study was conducted at a single academic medical center and results might not be generalizable to other centers. The study included a mix of cancer types and stages, and it is possible that focusing on a specific cancer type, stage, or type of clinical trial (phase I, II, or III) could lead to different results. The study was cross-sectional and we did not track enrollment rates over time if patients were offered trials. Future studies should explore these findings in diverse settings longitudinally to confirm our results. Studies could also explore the role of DAs about specific cancer clinical trials rather than trials in general. Results are presented as mean (SD). UC = Usual Care. DA = Decision Aid. 2) Cancer research studies are the best way to find out whether one treatment is better than another. 3) Cancer research studies are only offered when the doctor thinks there are no other treatment options for a patient. 4) A patient can choose to stop being in a cancer research study at any time, even after he or she has signed the consent form and the study has started. 5) A patient can only be in a research study if his or her doctor recommends it. 6) A cancer research study could not be offered to a patient unless the new drug has been tested for safety in animals. 7) Cancer research studies almost never involve the use of a placebo or sugar pill alone. 8) Cancer research studies follow strict guidelines that are described in the study protocol. 9) A patient has to be in a research study if his or her doctor recommends it. 10) Patients are asked to take part in cancer research studies only when no other treatment options are available. 11) A phase III cancer research study focuses on finding the safety of new treatments.
CONCLUSIONS
